Sunday, September 13, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 12, 2026

Stocks to Love in 2026

View original at nasdaq.com
Stocks to Love in 2026 In this podcast, Motley Fool contributors Travis Hoium, Lou Whiteman, and Rachel Warren discuss: Why space is worth watching in 2026.Opportunities in healthcare.How Hims & Hers is disrupting the healthcare industry To catch full episodes of all The Motley Fool's free podcasts, check out our podca…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AI can absorb more real-time patient data than human doctors, such as Garmin watch health data integration

    80% confidence
  • Raised concerns about TransMedics Medicare reimbursement

    80% confidence
  • Space investments are high-risk, high-reward

    80% confidence
  • Expected to move toward profitability in 2026

    80% confidence
  • AI has potential to remember/process more medical information than single human physician

    80% confidence
  • Redwire is owning the fundamental building blocks if we're going to have a Golden Age in space

    80% confidence
  • Healthcare is a market that desperately needs disruption, but it's also between regulation and it is life or death

    80% confidence
  • Discussed data centers in space with solar power opportunity, more than 5 years away

    80% confidence
  • Prefers Rocket Lab over SpaceX, even if SpaceX was public

    80% confidence
  • Rocket Lab wants to get Neutron launch right the first time, unlike SpaceX's iterative explosion approach

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Keeps Flowing as Enterprise Adoption and Government Contracts Validate the Bet
A late-August surge of nine-figure funding rounds (Socure, Stability AI, Generalist AI, Gatik, Regent Craft, Emerald AI, Owner) shows venture capital still pouring into AI infrastructure, identity/fintech, and autonomy, even as public-market sentiment stays jumpy — Palantir's stock fell 6% the same week it landed the Army's TITAN contract. UiPath's raised guidance and strong Q2 results, alongside efficiency breakthroughs like Multiverse Computing's model compression, point to real enterprise monetization catching up to the funding hype.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,280 source documents archived
Query this data → isubstrate.com